Can Anyone Use Mounjaro for Weight Loss?

What the approved guidance says about who qualifies

The UK licence for Mounjaro, granted by the MHRA and summarised on the NHS tirzepatide medicine page, sets out the licensed population clearly: adults aged 18 and over with a BMI of 30 or above, or a BMI between 27 and 29.9 alongside at least one weight-related health condition. Conditions that count include type 2 diabetes, high blood pressure, raised cholesterol, obstructive sleep apnoea and cardiovascular disease. Treatment is intended as an addition to a reduced-calorie diet and increased physical activity, not a standalone fix.

Those who cannot use Mounjaro include anyone who is pregnant, breastfeeding, or planning to conceive in the near term. The medicine is not licensed for under-18s. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 need to discuss this with a prescriber before considering treatment, as do those who have experienced pancreatitis. These exclusions are not bureaucratic caution; they reflect specific biological risks identified during clinical development and post-authorisation monitoring.

It is worth knowing that ethnic background can affect where the BMI threshold sits. UK clinical guidance reduces the qualifying BMI by 2.5 kg/m² for adults of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, recognising that cardiometabolic risk presents at lower BMI values in those groups. Our full eligibility breakdown walks through these nuances in detail.

What the trial evidence tells us about who benefits

NICE's appraisal of tirzepatide, TA1026, drew on the SURMOUNT clinical programme, a series of trials randomising thousands of adults with obesity to tirzepatide or placebo alongside lifestyle support. SURMOUNT-1 alone enrolled 2,539 participants and produced average body-weight reductions of around 20 to 21 percent at the highest dose over 72 weeks, figures that were substantially higher than those seen with placebo. A question our prescribers hear most weeks is whether those results apply to everyone who starts treatment, and the honest answer is no. Participants who adhered closely to the programme and made meaningful dietary changes tended to see the strongest outcomes. Some people lose less, and our page exploring what people have experienced using Mounjaro after 30 days gives a realistic picture of how outcomes can vary over time. A separate page explores what happens when weight loss stalls on Mounjaro and what the clinical options are at that point.

The trial populations were adults with established obesity and, in several arms, related metabolic conditions. That profile maps closely onto the licensed criteria, which is deliberate: regulators licence medicines for the people in whom they were tested. Using tirzepatide outside that population (for example, to lose a small amount of weight for cosmetic purposes) falls outside the licence and outside what MHRA and DHSC guidance considers appropriate. The MHRA has stated explicitly that GLP-1 medicines are not assessed for quick or cosmetic weight loss. More background on the medicine itself is on our tirzepatide overview.

Private versus NHS criteria: why they differ

For the NHS, NICE recommends tirzepatide only for adults with a BMI of 35 or above and at least one weight-related comorbidity, delivered through a structured NHS weight management pathway. Access is being phased in gradually, from June 2025, people with a BMI of 40 or above and four or more qualifying conditions became eligible; the cohort expanded to include BMI 35 to 39.9 from June 2026. NHS eligibility is therefore considerably narrower than the licensed SmPC criteria.

Private prescribing follows the SmPC, not the NICE cost-effectiveness model. That means a prescriber can lawfully consider treatment for someone with a BMI of 30, or 27 with a qualifying condition, as long as contraindications are absent and the overall clinical picture supports it. Understanding the cost context is part of making an informed choice, our page on the Eli Lilly UK price increase sets out what happened to Mounjaro pricing from September 2025 and how that affects private costs today. For people weighing up their options, our weight loss treatments overview covers the full range of licensed approaches.

What happens at a clinical assessment, and how to check you are using a legitimate service

The assessment process exists precisely because the criteria above are not self-scoring. A prescriber looks beyond the BMI number: current medications that could interact, existing conditions, history of relevant diagnoses, and whether the expected benefit outweighs any individual risk. For tirzepatide, women using oral contraceptives are advised to add a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because gastric slowing can reduce pill absorption. That kind of detail only surfaces in a proper clinical review.

At nume, every consultation is read by a GPhC-registered Independent Prescriber (a real clinician, not software) on the day it is submitted. Identity is verified with photo ID, and weight is confirmed on a live video call. If you want to check our pharmacy registration yourself, the GPhC register entry for our pharmacy (registration number 9012878) is publicly searchable at pharmacyregulation.org. More about the team behind our clinical decisions is on the clinical team page. If you are already exploring whether treatment is right for you, our guide to accessing Mounjaro covers the practical route in full. And if you have questions before committing, the FAQs and contact page are there.

Mounjaro is genuinely effective for the people it is designed for. The criteria exist to protect the people it is not. If you are unsure whether you fall within them, the right step is a consultation with a prescriber rather than a guess. Start your free consultation and a clinician will assess your situation the same day.